Vectus Biosystems Ltd

Research Vectus Biosystems Ltd (VBS) on Bullrun: market cap AUD 7.69M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVBS
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 7.69M
• Financial periodFY2024
• Net income-AUD 2.34M
• Free cash flow-AUD 2.10M

Valuation Snapshot

latest market cap is AUD 7.69M.

About Vectus Biosystems Ltd

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring.

Frequently asked questions

What is Vectus Biosystems Ltd's market cap?

Vectus Biosystems Ltd's market capitalization is AUD 7.69M.

What does Vectus Biosystems Ltd do?

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis.